ClinicalTrials.gg
CompletedNCT02525939dal-GenEUpdated Oct 12, 2022Results posted

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

A Phase 3 interventional study of dalcetrapib and Placebo in Acute Coronary Syndrome, sponsored by DalCor Pharmaceuticals. Completed at 563 sites in 32 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2022-10-12.

Sponsored by DalCor Pharmaceuticals · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,147
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.

Enrollment
21st of 186
6,147 · median 150
Started
2016
with 12 others
Phase 3
40 of 265
1 open now
Registered
164th of 265
by date

Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 21st largest by enrollment of the 186 interventional ones that give a count, is one of 13 that started in 2016, is one of 40 in phase 3, and was the 164th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Acute Coronary Syndrome with a site in United States, or all of them as a file.
02

Study summary

A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in the hospital and will continue following release from the hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (4-12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.

Read the detailed description

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints.

Those who are likely to qualify will undergo Genotype Assay Testing to evaluate genetic determination or the presence of the AA genotype. The test is investigational and test procedures are Roche Molecular Diagnostics protocol ADCY9-COB-389.

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with the appropriate genetic background and recently hospitalized for ACS (between 4 and 12 weeks following the index event), will be enrolled in this trial.
  • AA genotype at variant gene as determined by Genotype Assay testing, conducted at a designated testing site (ITS)
  • Clinically stable, ie, free of ischemic symptoms at rest or with minimal exertion for at least 1 week prior to randomization
  • Prior to randomization, subject must have evidence of guidelines-based management of LDL-C, at a minimum to include medical and dietary treatment to a target level of LDL-C \<100 mg/dl (\<2.6 mmol/L).

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant (negative pregnancy test required for all women of at Visit 2, Day 0) or breast-feeding
  • Women of childbearing potential (women who are not surgically sterile or defined as amenorrhea for >12 months) who are not using at least one method of *
  • (NYHA) Class III or IV heart failure
  • Last known \<10 g/dL
  • Index ACS event presumed due to uncontrolled hypertension

(*) Varies by region

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6,147 participants (actual)

Study arms

  • Active comparator
    Dalcetrapib

    Participants received dalcetrapib 600 mg (two 300 mg tablets) orally once daily. dalcetrapib: Cholesterol Ester Transfer Protein inhibitor, 300 mg tablets

    Drug: dalcetrapib

  • Placebo comparator
    Placebo

    Participants received dalcetrapib placebo tablets matching dalcetrapib orally once daily. Placebo: dalcetrapib matching placebo tablets

    Drug: Placebo

Interventions

  • Cholesterol Ester Transfer Protein inhibitor

  • DrugPlacebo

    matching placebo tablets

06

What researchers measure

Primary outcomes

  1. Composite of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, and Non-Fatal Stroke

    All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The primary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite endpoint, which included death from cardiovascular causes, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke, as positively adjudicated by the CEC.

    Time frame: From randomization to the first occurrence of any component of the composite primary endpoint (median duration of follow-up was 39.9 months)

Secondary outcomes

  1. Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke, Hospitalization for ACS (With Electrocardiogram Abnormalities) or Unanticipated Coronary Revascularization

    All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The primary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite endpoint, which included death from cardiovascular causes, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, hospitalization for acute coronary syndrome (with electrocardiogram abnormalities) or unanticipated coronary revascularization, as positively adjudicated by the CEC.

    Time frame: From randomization to the first occurrence of any component of the composite secondary endpoint (median duration of follow-up was 39.9 months)

  2. Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke or Hospitalization for New or Worsening Heart Failure

    All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The secondary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite secondary endpoint, which included death from cardiovascular causes, cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for new or worsening heart failure, as positively adjudicated by the CEC.

    Time frame: From randomization to the first occurrence of any component of the composite secondary endpoint (median duration of follow-up was 39.9 months)

07

Results

Posted Oct 12, 2022
Limitations and caveats
The main limitation of this study is the occurrence of the COVID-19 pandemic during study conduct.

Participant flow

Trial enrolment began in April 2016 and was completed in December 2018. A total of 45,005 patients with recent acute coronary syndrome were screened in order to identify participants meeting the single genetic criterion (AA genotype at rs1967309 in the ADCY9 gene) and other inclusion criteria and no exclusion criteria required for randomization.

Participant flow — Overall Study
MilestoneDalcetrapibPlacebo
Started30713076
Took study medication30643064
Completed28402833
Not completed231243
Withdrew: Lost to follow-up2724
Withdrew: Physician decision01
Withdrew: Withdrawal by subject2439
Withdrew: Death180179

Outcome measures

PrimaryComposite of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, and Non-Fatal Stroke

All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The primary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite endpoint, which included death from cardiovascular causes, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke, as positively adjudicated by the CEC.

Time frame:
From randomization to the first occurrence of any component of the composite primary endpoint (median duration of follow-up was 39.9 months)
Reported as:
Count of participants · Participants
Composite of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, and Non-Fatal Stroke
ParticipantsPlaceboDalcetrapib
Composite of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, and Non-Fatal Stroke327292
Statistical analysis
  • Placebo vs Dalcetrapib · Stratified Cox proportional hazard model · p = 0.12 (The estimated HR was presented with a 95% CI and a p-value. The primary analysis was conducted at the 0.05 significance level.) · Hazard ratio (hr): 0.88 · 95% CI 0.75 to 1.03
SecondaryComposite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke, Hospitalization for ACS (With Electrocardiogram Abnormalities) or Unanticipated Coronary Revascularization

All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The primary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite endpoint, which included death from cardiovascular causes, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, hospitalization for acute coronary syndrome (with electrocardiogram abnormalities) or unanticipated coronary revascularization, as positively adjudicated by the CEC.

Time frame:
From randomization to the first occurrence of any component of the composite secondary endpoint (median duration of follow-up was 39.9 months)
Reported as:
Count of participants · Participants
Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke, Hospitalization for ACS (With Electrocardiogram Abnormalities) or Unanticipated Coronary Revascularization
ParticipantsPlaceboDalcetrapib
Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke, Hospitalization for ACS (With Electrocardiogram Abnormalities) or Unanticipated Coronary Revascularization471471
Statistical analysis
  • Placebo vs Dalcetrapib · Stratified Cox proportional hazard model · p = 0.95 · Hazard ratio (hr): 1.00 · 95% CI 0.88 to 1.13
SecondaryComposite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke or Hospitalization for New or Worsening Heart Failure

All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The secondary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite secondary endpoint, which included death from cardiovascular causes, cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for new or worsening heart failure, as positively adjudicated by the CEC.

Time frame:
From randomization to the first occurrence of any component of the composite secondary endpoint (median duration of follow-up was 39.9 months)
Reported as:
Count of participants · Participants
Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke or Hospitalization for New or Worsening Heart Failure
ParticipantsPlaceboDalcetrapib
Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke or Hospitalization for New or Worsening Heart Failure346321
Statistical analysis
  • Placebo vs Dalcetrapib · Stratified Cox proportional hazard model · p = 0.27 · Hazard ratio (hr): 0.92 · 95% CI 0.79 to 1.07

Adverse events

Collected over From randomization through 14 days after end of study (median duration of follow-up was 39.9 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo180/3,076 (5.9%)923/3,076 (30%)818/3,076 (26.6%)
Dalcetrapib182/3,071 (5.9%)900/3,071 (29.3%)971/3,071 (31.6%)
Most frequent serious events
Showing 10 of 879
Most frequent serious events
EventPlaceboDalcetrapib
Chest painGeneral disorders79/307681/3071
Angina pectorisCardiac disorders50/307652/3071
Corona virus infectionInfections and infestations43/307645/3071
Non-cardiac chest painGeneral disorders28/307641/3071
PneumoniaInfections and infestations41/307639/3071
Atrial fibrillationCardiac disorders36/307631/3071
Coronary artery diseaseCardiac disorders23/307630/3071
SyncopeNervous system disorders28/307624/3071
OsteoarthritisMusculoskeletal and connective tissue disorders27/307623/3071
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)27/307610/3071
Most frequent other events
Most frequent other events
EventPlaceboDalcetrapib
DiarrhoeaGastrointestinal disorders186/3076300/3071
HypertensionVascular disorders266/3076277/3071
Chest painGeneral disorders239/3076268/3071
DyspnoeaRespiratory, thoracic and mediastinal disorders155/3076152/3071

Baseline characteristics

Age, Continuous
Age, Continuous(years)DalcetrapibPlaceboTotal
Mean62.19 ± 9.1662.34 ± 9.2562.26 ± 9.21
Sex: Female, Male
Sex: Female, Male(Participants)DalcetrapibPlaceboTotal
Female7236721395
Male234824044752
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DalcetrapibPlaceboTotal
Hispanic or Latino469469938
Not Hispanic or Latino255125505101
Unknown or Not Reported5157108
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DalcetrapibPlaceboTotal
American Indian or Alaska Native111223
Asian5859117
Native Hawaiian or Other Pacific Islander151530
Black or African American130123253
White277127985569
More than one race8568153
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)DalcetrapibPlaceboTotal
United Arab Emirates9716
Argentina7474148
Australia100102202
Austria232750
Belgium221739
Bulgaria201185386
Brazil218213431
Canada209228437
Switzerland211536
Chile445094
Czechia7378151
Germany284169
Denmark6671137
Spain84104188
Finland91120
France495099
United Kingdom200183383
Hungary82101183
Israel198175373
Italy6954123
Netherlands129147276
New Zealand7574149
Poland166169335
Puerto Rico10414
Romania9287179
Russia215240455
Slovakia212748
Sweden353065
Turkey312657
United States370358728
South Africa121101222
Portugal272754
Reproductive status if female
Reproductive status if female(Participants)DalcetrapibPlaceboTotal
Childbearing potential with double contraceptive protection242448
Childbearing potential without double contraceptive potential112
Postmenopausal6025841186
Surgically sterilized9260152
Other437
Acute Coronary Syndrome (ACS) Index Event Details:
Acute Coronary Syndrome (ACS) Index Event Details:(days)DalcetrapibPlaceboTotal
Time since ACS index event53.82 ± 18.0954.01 ± 18.3153.91 ± 18.20
Hospitalization duration6.06 ± 4.336.22 ± 5.036.14 ± 4.69
Acute Coronary Syndrome (ACS) Index Event Diagnosis
Acute Coronary Syndrome (ACS) Index Event Diagnosis(Participants)DalcetrapibPlaceboTotal
Spontaneous Myocardial Infarction (MI)275627425498
Procedure-related Myocardial Infarction (MI) after Percutaneous Coronary Intervention (PCI)202848
Hospitalization for Acute Coronary Syndrome (Electrocardiogram abnormalities without biomarkers)295306601

1 further baseline measures are reported on the registry.

08

Study locations

563 sites
  • Research Site
    Alexander City, Alabama, United States
  • Research Site
    Huntsville, Alabama, United States
  • Research Site
    Mobile, Alabama, United States
  • Research Site
    Cottonwood, Arizona, United States
  • Research Site
    Glendale, Arizona, United States
  • Research Site
    Jonesboro, Arkansas, United States
  • Research Site
    Huntington Beach, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Torrance, California, United States
  • Research Site
    Denver, Colorado, United States
  • Research Site
    Littleton, Colorado, United States
  • Research Site
    Danbury, Connecticut, United States
  • Research Site
    Hartford, Connecticut, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Clearwater, Florida, United States
  • Research Site
    Daytona Beach, Florida, United States
  • Research Site
    Fort Lauderdale, Florida, United States
  • Research Site
    Gainesville, Florida, United States
  • Research Site
    Homestead, Florida, United States
  • Research Site
    Hudson, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Largo, Florida, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Miramar, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Pembroke Pines, Florida, United States
  • Research Site
    Pensacola, Florida, United States
  • Research Site
    Port Charlotte, Florida, United States
  • Research Site
    Safety Harbor, Florida, United States
  • Research Site
    Tallahassee, Florida, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Columbus, Georgia, United States
  • Research Site
    Covington, Georgia, United States
  • Research Site
    Decatur, Georgia, United States
  • Research Site
    Macon, Georgia, United States
  • Research Site
    Evanston, Illinois, United States
  • Research Site
    Jerseyville, Illinois, United States
  • Research Site
    Fort Wayne, Indiana, United States
  • Research Site
    Newburgh, Indiana, United States
  • Research Site
    West Des Moines, Iowa, United States
  • Research Site
    Wichita, Kansas, United States
  • Research Site
    Owensboro, Kentucky, United States
  • Research Site
    Alexandria, Louisiana, United States
  • Research Site
    Covington, Louisiana, United States
  • Research Site
    Bangor, Maine, United States
  • Research Site
    Biddeford, Maine, United States
  • Research Site
    Lewiston, Maine, United States
  • Research Site
    Annapolis, Maryland, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Bethesda, Maryland, United States
  • Research Site
    Columbia, Maryland, United States
  • Research Site
    Salisbury, Maryland, United States
  • Research Site
    Hyannis, Massachusetts, United States
  • Research Site
    Alpena, Michigan, United States
  • Research Site
    Bay City, Michigan, United States
  • Research Site
    Lansing, Michigan, United States
  • Research Site
    Midland, Michigan, United States
  • Research Site
    Mount Clemens, Michigan, United States
  • Research Site
    Muskegon, Michigan, United States
  • Research Site
    Saginaw, Michigan, United States
  • Research Site
    Saint Joseph, Michigan, United States
  • Research Site
    Ypsilanti, Michigan, United States
  • Research Site
    Coon Rapids, Minnesota, United States
  • Research Site
    Duluth, Minnesota, United States
  • Research Site
    Minneapolis, Minnesota, United States
  • Research Site
    Saint Cloud, Minnesota, United States
  • Research Site
    Saint Louis, Missouri, United States
  • Research Site
    Washington, Missouri, United States
  • Research Site
    Missoula, Montana, United States
  • Research Site
    Omaha, Nebraska, United States
  • Research Site
    Las Vegas, Nevada, United States
  • Research Site
    Bridgewater, New Jersey, United States
  • Research Site
    Linden, New Jersey, United States
  • Research Site
    Somerset, New Jersey, United States
  • Research Site
    Summit, New Jersey, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    Buffalo, New York, United States
  • Research Site
    Johnson City, New York, United States
  • Research Site
    New Windsor, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Poughkeepsie, New York, United States
  • Research Site
    Asheville, North Carolina, United States
  • Research Site
    Greensboro, North Carolina, United States
  • Research Site
    Pinehurst, North Carolina, United States
  • Research Site
    Rocky Mount, North Carolina, United States
  • Research Site
    Wilmington, North Carolina, United States
  • Research Site
    Winston-Salem, North Carolina, United States
  • Research Site
    Minot, North Dakota, United States
  • Research Site
    Canton, Ohio, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Columbus, Ohio, United States
  • Research Site
    Springfield, Ohio, United States
  • Research Site
    Toledo, Ohio, United States
  • Research Site
    Zanesville, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Butler, Pennsylvania, United States
  • Research Site
    Chambersburg, Pennsylvania, United States
  • Research Site
    Erie, Pennsylvania, United States
  • Research Site
    Hershey, Pennsylvania, United States
  • Research Site
    Langhorne, Pennsylvania, United States

Showing the first 100 of 563 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tardif JC, Pfeffer MA, Kouz S, Koenig W, Maggioni AP, McMurray JJV, Mooser V, Waters DD, Gregoire JC, L'Allier PL, Wouter Jukema J, White HD, Heinonen T, Black DM, Laghrissi-Thode F, Levesque S, Guertin MC, Dube MP; dal-GenE Investigators. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. Eur Heart J. 2022 Oct 14;43(39):3947-3956. doi: 10.1093/eurheartj/ehac374. Erratum In: Eur Heart J. 2022 Nov 21;43(44):4656. doi: 10.1093/eurheartj/ehac534. PubMed 35856777 ↗
  • Black DM, Miller M, Heinonen TM, Zhang G. Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition. J Cardiovasc Pharmacol. 2021 Oct 1;78(4):496-500. doi: 10.1097/FJC.0000000000001093. PubMed 34173811 ↗
  • Tardif JC, Dube MP, Pfeffer MA, Waters DD, Koenig W, Maggioni AP, McMurray JJV, Mooser V, White HD, Heinonen T, Black DM, Guertin MC; dal-GenE Investigators. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. Am Heart J. 2020 Apr;222:157-165. doi: 10.1016/j.ahj.2020.01.007. Epub 2020 Jan 17. PubMed 32087417 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Oct 2021, 66 months.

Results were first posted in Oct 2022, 1 year after primary completion.

Of 39 phase 3 interventional studies under Acute Coronary Syndrome, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 66 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2015
First posted
Aug 18, 2015
StartActual
Apr 2016
Primary completionActual
Oct 2021
CompletionActual
Oct 2021
Results first posted
Oct 12, 2022
Last update
Oct 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02525939
Lead sponsor
DalCor Pharmaceuticals
Collaborators
The Montreal Health Innovations Coordinating Center (MHICC), Medpace, Inc., Roche Molecular Systems, Inc
Responsible party
Sponsor
First posted
Aug 18, 2015
Start date
Apr 2016
Primary completion
Oct 2021
Completion
Oct 2021
Results posted
Oct 12, 2022
Last update
Oct 12, 2022

Study contacts

Donald M Black, MD
study director · DalCor Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalcetrapib

Start the discussion